The mission of the Cancer Risk and Disparities Program is to support research that will lead to a reduction of cancer risk and disparities across society. To achieve this goal, the Program has the following four specific aims: 1. Understand the individual, psychosocial, organizational and community-level factors that determine differences in cancer risk across the life course and population groups. 2. Develop, test and evaluate interventions to reduce cancer risk across the life course and population groups. 3. Advance the science of communication and knowledge translation to promote dissemination of evidence-based interventions to reduce cancer risk. 4. Examine causes of disparities in cancer risk and incidence and Identify interventions to redress these disparities. The Program was initially funded in 2000 when the Dana-Farber/Harvard Cancer Center was established as a consortium Center, and received a merit score of """"""""excellent to outstanding"""""""" at the time of the last renewal in 2005. The Program Is led by L. Frazier(DFCI). There are two Co-Leaders: K. Viswanath (DFCI) and D. Williams(HSPH). During the current project period, the goals of the Program were substantially revised to include new research foci including: 1) the individual and societal factors that predispose to cancer risk, 2) the science of dissemination and 3) an explicit focus on cancer disparities, all of which represent expanded and vibrant strengths within the Program. The expertise of the 49 members spans epidemiology, molecular epidemiology, behavioral science, communication science, intervention science, health policy and dissemination. In 2009, the Program received $19.7 million in cancer-relevant funding (total costs), which included over $11.9 million in NCI funding and $6.5 million in other federal, peer-reviewed funding. Attesting to the productivity and interactivity of the Program are the 903 publications authored by members of the Program during the project period (2006 to 2010), of which 15.5% were Intra-programmatic ,18% were inter-programmatic and 16% were inter-institutional collaborations.

Public Health Relevance

The Cancer Risk and Disparities Program seeks to identify the causes of increased risk of cancer, to design interventions to address these causes and to disseminate this knowledge effecfively into the community by advancing the methodologies of communication science and knowledge translafion. The Program is committed to reducing the incidence of cancer and its unequal distribution in the US population through its research and involvement in health and social policy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601465
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$81,766
Indirect Cost
$60,777
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:
Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028
Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318
Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682
Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503
Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288
Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547
Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268
Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359
Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727

Showing the most recent 10 out of 371 publications